Chongqing Taiji Industry Group Co Ltd
SSE:600129
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (24.3), the stock would be worth ¥17.37 (9% upside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 22.3 | ¥15.96 |
0%
|
| 3-Year Average | 24.3 | ¥17.37 |
+9%
|
| 5-Year Average | 21.8 | ¥15.57 |
-2%
|
| Industry Average | 23.8 | ¥16.98 |
+6%
|
| Country Average | 20.8 | ¥14.87 |
-7%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
C
|
Chongqing Taiji Industry Group Co Ltd
SSE:600129
|
8.8B CNY | 22.3 | 73 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 51.6 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 23.4 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 15.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 21.1 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 15.2 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 18.8 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 936 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 10.5 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 17.2 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 10.6 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.5 |
| Median | 20.8 |
| 70th Percentile | 39.2 |
| Max | 266 666.7 |
Other Multiples
Chongqing Taiji Industry Group Co Ltd
Glance View
Amidst the sprawling urban landscape of Chongqing, a city often enveloped in a mystical cloak of fog, stands Chongqing Taiji Industry Group Co Ltd., a distinguished entity in the realm of pharmaceuticals. Commanding a legacy that spans over a century, Taiji Industry has mastered the delicate fusion of traditional Chinese medicine with modern pharmaceutical processes. This synthesis has propelled the company to the forefront of China's healthcare sector. The company’s operations revolve around robust research and development, manufacturing, and distribution, focusing on a diverse array of pharmaceutical products, health supplements, and TCM (Traditional Chinese Medicine) remedies. Seamlessly integrating innovation with traditional wisdom, the group has built an extensive portfolio catering to a wide range of medical needs, from cardiovascular treatments to neurological supports. Financially, Taiji Industry's prowess is underpinned by its diverse revenue streams, primarily flowing from its broad spectrum of medicinal drugs and health products. The company has capitalized on its established brand and extensive distribution networks, which span across the vast Chinese landscape and extend their reach into international markets. Their stronghold in distribution is further solidified by strategic collaborations with healthcare providers and retail pharmacy chains, ensuring reliable market penetration and accessibility to the end consumer. This well-oiled machine not only secures Taiji's position as a major pharmaceutical player but also drives its financial growth, allowing the company to invest continuously in innovation, quality enhancement, and market expansion. The synergistic blend of tradition and modernity continues to propel Taiji Industry through the ever-evolving pharmaceutical landscape.